Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(852)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Apr 26, 2024 10:12pm
RE:RE:Another week almost over, recap
notable, I appreciate your never ending posts if semi- relevant information. I get the connections etc. this is the second or third time you try to equate my posts with trades? Respectfully
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 9:13pm
RE:RE:RE:Type C Meeting Timings
April 26, 2024 - Cancer biomarkers https://www.patientpower.info/navigating-cancer/cancer-biomarkers
New PEA Indicates an Ultra Low-Cost Uranium Project with Huge Exploration Upside
posted Apr 26, 2024 9:00am by
Blue Sky Uranium Corp
-
|
This PEA reaffirms that the deposit is a leading low-cost uranium-vanadium project. We believe that this resurgent uranium market has a strong long-term outlook and we are therefore preparing to complete a prefeasibility study as soon as possible ...read more
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Apr 26, 2024 4:09pm
@ the Bell: Despite earlier struggles, TSX finishes the week higher
The mining sector was the biggest gainer on the TSX while declines in the energy sector offered the most drag.
read article.
(109)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Apr 26, 2024 3:41pm
RE:Another week almost over, recap
There sure doesn't seem to be any pomp and pageantry over any upcoming news. 11,000 shares today is pitiful. I love your positive vibes, but it's sure not a market wide feeling.
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 2:03pm
RE:Another week almost over, recap
As soon as this airy fairy xanadoo thread went up, someone hit the bid and the stock went down - which only means that xanadoo's posts are front running his trades.
(852)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Apr 26, 2024 1:49pm
Another week almost over, recap
Hello all; Yet another week is almost over. Acutually 3 more trading days & a new month. Did anything important or significant happen this week? Regarding my comments, I have extream myopia
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 1:48pm
RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
April 26, 2024 - After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, TROP2-directed antibody-drug conjugate (ADC), which serves as the
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 1:30pm
RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employees
April 26, 2024 - Gilead quietly provided an update on [its CD47] program after the market closed Thursday, removing all solid tumor trials of the CD47 drug candidate from its pipeline as part of its
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 1:10pm
RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus
https://www.tiktok.com/@drteplinsky/video/7354838139112000814
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 1:09pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
https://www.tiktok.com/@drteplinsky/video/7354838139112000814
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 1:07pm
RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36009698
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 12:54pm
RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
“When it comes to immunotherapy, one of the most important findings that we’ve made in the last several years is an understanding of the targets of the immune system on the cancer,” Rosenberg said
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 12:46pm
RE:RE:RE:CD8+ TiLs and T-cell exhaustion
April 21, 2024 - "It took more than 35 years for tumor-infiltrating lymphocytes, which Steven A. Rosenberg, MD, PhD, and colleagues first reported on in 1988 for the treatment of
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 11:39am
RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
April 02, 2024 - Mayo Clinic - "Five years after surgery, 95% of participants with small tumors, stage 1 TNBC, and whose tumors had high TILs were alive, compared to 82% of patients
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 11:26am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer
https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=35937603 The Scientist - regarding CAR-T cells on TiLs - TCR complex Dr. Michel Sadelian, originally from Alberta
...more
(5343)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 26, 2024 11:20am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer
ONCY reported on TCR sequencing in the recent GOBLET Phase 1/2 clinical trial in metastatic pancreatic cancer. TCR sequencing is a technique that measures the diversity and clonality of T
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update